Acutaas FY26 PAT surges 122% to ₹3,564 Mn
Acutaas Chemicals released its corporate presentation for investor meets scheduled from May 27 to June 16, 2026. For FY26, the company reported a 33% increase in revenue to ₹13,394 Mn and a 122% surge in PAT to ₹3,564 Mn, with margins expanding to 26.6%. The firm is investing ₹1000+ Cr. across Pharma, Battery, and Semiconductor segments to drive future growth.
*this image is generated using AI for illustrative purposes only.
Acutaas Chemicals Limited has released its corporate presentation for investor conferences scheduled between May 27 and June 16, 2026. The disclosure, filed on May 16, 2026, outlines the company's financial performance for FY26 and its strategic growth initiatives. Company officials will attend one-on-one and group meetings across Mumbai, Hong Kong, Singapore, and London to discuss these developments.
Financial Performance
The company reported a Profit After Tax (PAT) of ₹ 3,564 Mn for FY26, a significant increase from ₹ 1,604 Mn in FY25. The PAT margin for FY26 stood at 26.6%. Revenue from operations for FY26 rose to ₹ 13,394 Mn, compared to ₹ 10,069 Mn in the previous fiscal year. EBITDA for FY26 was ₹ 4,804 Mn, with an EBITDA margin of 35.9%.
| Metric | FY25 | FY26 |
|---|---|---|
| Revenue from Operations (₹ Mn) | 10,069 | 13,394 |
| PAT (₹ Mn) | 1,604 | 3,564 |
| PAT Margin (%) | 15.9% | 26.6% |
| EBITDA (₹ Mn) | 2,321 | 4,804 |
| EBITDA Margin (%) | 23.0% | 35.9% |
Business Overview
Acutaas Chemicals operates across four primary segments: Pharmaceutical Intermediates, Semiconductor Chemicals, Battery Chemicals, and Commodity Chemicals. The Pharmaceutical Intermediates segment contributed 87.7% to the total revenue, generating ₹ 11,741 Mn in FY26. The company holds a 50-90% global market share in key intermediates and is the only manufacturer in India for photoresist chemicals.
Growth Strategy
The company is investing ₹ 1000+ Cr. for sustainable future growth from FY23 to FY30. This includes significant capital expenditure in Pharma, Battery, and Semiconductor segments. The Pharma segment has completed a 3x capacity expansion at the Ankleshwar site. The Battery Chemicals segment is ongoing with a total capex of ~ ₹ 220 Cr., while the Semiconductor segment is investing ~ ₹ 200 Cr. in its joint venture, Indichem, in South Korea.
Investor Conference Schedule
The company has outlined participation in four distinct conference events:
| Conference Date | Conference Name | Location |
|---|---|---|
| May 27 & 29, 2026 | 360 ONE Capital (B&K) 16th Annual Investor Conference | Mumbai |
| June 8, 2026 | Kotak India Corporate Day | Hong Kong |
| June 9 & 10, 2026 | Kotak India Corporate Day | Singapore |
| June 15 & 16, 2026 | Kotak India Corporate Day | London |
Acutaas Chemicals clarified that no unpublished price-sensitive information is intended to be discussed during these conferences. The corporate presentation is available on the company's website.
Historical Stock Returns for Acutaas Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.45% | +2.71% | +14.79% | +96.95% | +190.09% | +587.27% |
How quickly could the Battery Chemicals segment transition from validation to commercial revenue, and what revenue contribution could it realistically achieve by FY28 given the 2,000 MTPA Phase 1 capacity?
With the Indichem JV semiconductor facility in South Korea under construction, how might geopolitical tensions or shifts in global semiconductor supply chains affect Acutaas's ability to capture market share in photoresist and related chemicals?
Given the dramatic EBITDA margin expansion from 23% to 35.9% in a single year, what structural factors are driving this improvement and how sustainable are these margins if raw material costs or competitive dynamics shift?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
